扎那米韦
唾液酸酶
病毒
部分
活动站点
磺酸盐
甲型流感病毒
病毒学
化学
结合位点
体外
神经氨酸酶
病毒复制
正粘病毒科
生物化学
生物
立体化学
酶
医学
2019年冠状病毒病(COVID-19)
传染病(医学专业)
钠
有机化学
疾病
病理
作者
Ádám Hadházi,Linghui Li,Benjamin Bailly,Andrea Maggioni,Gael Martin,Larissa Dirr,Jeffrey C. Dyason,Robin J. Thomson,George F. Gao,Anikó Borbás,Thomas Ve,Mauro Pascolutti,Mark von Itzstein
出处
期刊:ChemMedChem
[Wiley]
日期:2018-03-15
卷期号:13 (8): 785-789
被引量:24
标识
DOI:10.1002/cmdc.201800092
摘要
Influenza virus infection continues to cause significant, often severe, respiratory illness worldwide. A validated target for the development of anti‐influenza agents is the virus surface protein sialidase. In the current study, we have discovered a highly potent inhibitor of influenza virus sialidase, based on a novel sialosyl sulfonate template. The synthesised 3‐guanidino sialosyl α‐sulfonate, a sulfonozanamivir analogue, inhibits viral replication in vitro at the nanomolar level, comparable to that of the anti‐influenza drug zanamivir. Using protein X‐ray crystallography we show that the sialosyl α‐sulfonate template binds within the sialidase active site in a 1C4 chair conformation. The C1‐sulfonate moiety forms crucial and strong‐binding interactions with the active site's triarginyl cluster, while the 3‐guanidino moiety interacts significantly with conserved active site residues. This sulfonozanamivir analogue provides a new direction in anti‐influenza virus drug development.
科研通智能强力驱动
Strongly Powered by AbleSci AI